MaaT Pharma (EPA:MAAT) Full Year 2022 Results
Key Financial Results
- Net loss: €13.7m (loss widened by 52% from FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
MaaT Pharma shares are up 5.3% from a week ago.
Risk Analysis
We should say that we've discovered 4 warning signs for MaaT Pharma (1 is a bit concerning!) that you should be aware of before investing here.
If you're looking to trade MaaT Pharma, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:MAAT
MaaT Pharma
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
Flawless balance sheet slight.
Market Insights
Community Narratives
